Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsConstruction in ProgressCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Inventory (2017 - 2025)

Dr Reddys Laboratories has reported Inventory over the past 9 years, most recently at $820.9 million for Q1 2025.

  • For Q1 2025, Inventory rose 7.27% year-over-year to $820.9 million; the TTM value through Mar 2025 reached $820.9 million, up 7.27%, while the annual FY2025 figure was $832.0 million, 9.04% up from the prior year.
  • Inventory for Q1 2025 was $820.9 million at Dr Reddys Laboratories, up from $765.3 million in the prior quarter.
  • Over five years, Inventory peaked at $820.9 million in Q1 2025 and troughed at $592.1 million in Q1 2023.
  • A 5-year average of $695.5 million and a median of $676.7 million in 2022 define the central range for Inventory.
  • Biggest five-year swings in Inventory: decreased 12.51% in 2023 and later rose 29.25% in 2024.
  • Year by year, Inventory stood at $622.8 million in 2021, then increased by 8.65% to $676.7 million in 2022, then fell by 12.51% to $592.1 million in 2023, then increased by 29.25% to $765.3 million in 2024, then rose by 7.27% to $820.9 million in 2025.
  • Business Quant data shows Inventory for RDY at $820.9 million in Q1 2025, $765.3 million in Q1 2024, and $592.1 million in Q1 2023.